midostaurin-pkc412

Description: Midostaurin (formerly also known as PKC-412, PKC-412A and CGP 41251; trade name: Rydapt), a synthetic indolocarbazole compound, is a multi-targeted kinase inhibitor which inhibits PKCalpha/beta/gamma, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRbeta and VEGFR1/2 with IC50 ranging from 80-500 NM and with potential antiangiogenic and antineoplastic activities. In April 2018, Midostaurin was approved by FDA to treat acute myeloid leukemia. Midostaurin is a synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits PKCalpha, VEGFR2, c-kit, PDGFR and FLT3, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.

References: Pharmacol Ther. 1999 May-Jun; 82(2-3):293-301; Jpn J Pharmacol. 1996 Jan; 70(1):65-72.

Related CAS: 179237-49-1 3-Hydroxy Midostaurin (CGP 52421)